share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/04/18 22:32

Moomoo AI 已提取核心訊息

On April 18, 2024, Adial Pharmaceuticals, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, enabling the sale of its common stock from time to time. The agreement allows for sales through a prospectus supplement and an accompanying base prospectus, which are part of a shelf registration statement declared effective by the SEC on January 24, 2024. The total market value of the common stock available for sale is approximately $4.28 million, subject to certain limitations. Sales may occur on the Nasdaq or other trading markets, and the Sales Agent may also conduct sales in privately negotiated transactions with the company's approval. Adial Pharmaceuticals will pay a 3.0% commission on gross proceeds to the Sales Agent and reimburse certain expenses. The offering will continue until all shares are sold or the agreement is terminated.
On April 18, 2024, Adial Pharmaceuticals, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, enabling the sale of its common stock from time to time. The agreement allows for sales through a prospectus supplement and an accompanying base prospectus, which are part of a shelf registration statement declared effective by the SEC on January 24, 2024. The total market value of the common stock available for sale is approximately $4.28 million, subject to certain limitations. Sales may occur on the Nasdaq or other trading markets, and the Sales Agent may also conduct sales in privately negotiated transactions with the company's approval. Adial Pharmaceuticals will pay a 3.0% commission on gross proceeds to the Sales Agent and reimburse certain expenses. The offering will continue until all shares are sold or the agreement is terminated.
2024年4月18日，Adial Pharmicals, Inc.宣佈與H.C. Wainwright & Co., LLC簽訂了市場發行協議，允許不時出售其普通股。該協議允許通過招股說明書補充文件和隨附的基本招股說明書進行銷售，這些招股說明書是美國證券交易委員會於2024年1月24日宣佈生效的貨架註冊聲明的一部分。可供出售的普通股的總市值約爲428萬美元，但有一定的限制。銷售可能發生在納斯達克或其他交易市場，經公司批准，銷售代理也可以在私下協商的交易中進行銷售。Adial Pharmicals將向銷售代理支付總收益的3.0％的佣金，並報銷某些費用。此次發行將持續到所有股票出售或協議終止爲止。
2024年4月18日，Adial Pharmicals, Inc.宣佈與H.C. Wainwright & Co., LLC簽訂了市場發行協議，允許不時出售其普通股。該協議允許通過招股說明書補充文件和隨附的基本招股說明書進行銷售，這些招股說明書是美國證券交易委員會於2024年1月24日宣佈生效的貨架註冊聲明的一部分。可供出售的普通股的總市值約爲428萬美元，但有一定的限制。銷售可能發生在納斯達克或其他交易市場，經公司批准，銷售代理也可以在私下協商的交易中進行銷售。Adial Pharmicals將向銷售代理支付總收益的3.0％的佣金，並報銷某些費用。此次發行將持續到所有股票出售或協議終止爲止。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間